Predisposing Factors for Post-stroke Epilepsy
Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · May 9, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand why some people develop epilepsy after having a stroke, a condition known as post-stroke epilepsy. The study aims to find out what factors might lead to this condition and whether sleep plays a role in its development. To do this, researchers will observe patients who have had their first stroke and compare them to healthy individuals. Participants will undergo several tests, including brain scans (MRI) and sleep studies (polysomnography), along with some blood tests to gather important information.
To be eligible for this study, you need to be a first-time stroke patient who is able to give consent, and before your stroke, you should have had a relatively good level of independence. However, if you've had previous strokes, brain surgery, or certain other medical conditions, you won’t be able to participate. The trial is currently recruiting participants aged between 65 and 74, and it welcomes all genders. If you join the study, you'll help researchers learn more about post-stroke epilepsy, which could lead to better care and treatment for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • First time stroke patients with capacity to consent, admitted to the stroke unit at St. Olavs hospital.
- • Modified Rankin Scale (mRS) ≤ 2 before the stroke
- Exclusion Criteria:
- • Previous stroke or brain surgery
- • Traumatic brain injuries
- • Neurodegenerative diseases
- • Brain tumors
- • Epilepsy before the stroke
- • Hydrocephalus
- • Aphasia
- • Serious psychiatric disorders
- • MRI incompatibility and claustrophobia
About Norwegian University Of Science And Technology
The Norwegian University of Science and Technology (NTNU) is a leading research institution dedicated to advancing knowledge and innovation in various scientific fields. Renowned for its commitment to interdisciplinary collaboration, NTNU plays a pivotal role in addressing global health challenges through rigorous clinical trials and research initiatives. The university's emphasis on cutting-edge technology and its strong partnerships with healthcare sectors position it as a key player in translational research, ensuring that findings contribute effectively to improving public health and patient care. With a focus on ethical standards and scientific integrity, NTNU is dedicated to fostering advancements that enhance the quality of life and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trondheim, , Norway
Patients applied
Trial Officials
Axel Sandvig, PhD prof
Principal Investigator
Norwegian Science and Technology University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported